Biocon Corporate Presentation

Novels: Q1 FY22 KEY HIGHLIGHTS Equillium had Positive End-of-Phase 1 meeting with the US FDA on Itolizumab for acute GvHD* To initiate a Phase 3 pivotal study on Itolizumab in first-line acute GvHD* in Q4 CY 2021 COMP** approved an Orphan Designation for Itolizumab for the treatment of acute and chronic GVHD* in EU Completed dosing for Phase 4 study of Itolizumab for treating CRS^ in moderate to severe ARDS* patients due to Covid-19 *Graft-versus-host disease ** Committee for Orphan Medicinal Products ^Cytokine Release Syndrome #Acute Respiratory Distress Syndrome ✓ Biocon 15

View entire presentation